Table 1.
Baseline clinical characteristics of the study patients
| MR sinus (n = 10) | MR AF (n = 12) | p value | |
|---|---|---|---|
| Age (years) | 56 ± 10 | 67 ± 7 | 0.007 |
| Male (%) | 2 (20.0 %) | 10 (83.3 %) | 0.008 |
| Creatinine (mg/dl) | 0.7 ± 0.2 | 1.2 ± 0.4 | <0.001 |
| White blood cell count (103/uL) | 6.5 ± 1.9 | 5.2 ± 1.3 | 0.069 |
| Body mass index (kg/m2) | 24.4 ± 2.1 | 23.9 ± 3.1 | 0.628 |
| Hypertension (%) | 3 (30.0 %) | 6 (50.0 %) | 0.415 |
| Diabetes mellitus (%) | 2 (20.0 %) | 3 (25.0 %) | 1.000 |
| Dyslipidemia (%) | 5 (50.0 %) | 1 (8.3 %) | 0.043 |
| Heart failure NYHA classification | 2.9 ± 0.3 | 2.9 ± 0.5 | 0.961 |
| Functional class II (%) | 1 (10.0 %) | 2 (16.7 %) | |
| Functional class III (%) | 9 (90.0 %) | 9 (75.0 %) | |
| Functional class IV (%) | 0 (0.0 %) | 1 (8.3 %) | |
| Advanced heart failure (%) | 9 (90.0 %) | 10 (83.3 %) | 0.571 |
| Aortic valve disease (%) | 0 (0.0 %) | 2 (16.7 %) | 0.481 |
| Tricuspid valve disease (%) | 2 (20 %) | 7 (58.3 %) | 0.099 |
| Left atrial pressure (mmHg) | 17.0 ± 8.4 | 19.3 ± 7.9 | 0.424 |
| Left atrial diameter (mm) | 41.9 ± 5.7 | 51.7 ± 8.6 | 0.007 |
| Left atrial ejection fraction (%) | 51.6 ± 17.7 | 38.2 ± 13.6 | 0.041 |
| Left ventricular end-diastolic diameter (mm) | 54.6 ± 5.3 | 62.4 ± 8.6 | 0.029 |
| Left ventricular end-systolic diameter (mm) | 34.3 ± 5.9 | 42.5 ± 7.7 | 0.019 |
| Left ventricular ejection fraction (%) | 66.1 ± 7.9 | 58.5 ± 10.4 | 0.086 |
| Beta-blockers (%) | 1 (10.0 %) | 4 (33.3 %) | 0.323 |
| Calcium channel blockers (%) | 1 (10.0 %) | 4 (33.3 %) | 0.323 |
| Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (%) | 10 (100.0 %) | 10 (83.3 %) | 0.481 |
| Statins (%) | 1 (10.0 %) | 0 (0.0 %) | 0.455 |
Data are presented as mean ± SD or number (percentage).
NYHA, New York Heart Association.